BCL9L and cancer: Therefore, our study may also provide a novel mechanism for targeting Wnt/β-catenin signaling to promote antitumor immunity by overcoming cDC1 dysfunction in TME, suggesting that targeting BCL9/BCL9L to improve NF-κB-dependent antigen presentation in tumors is a potential approach to cancer therapy.